respiratori
multiplex
pcr
panel
highli
sensit
specif
allow
clinician
identifi
like
causal
organ
patient
symptom
suggest
respiratori
infect
identifi
viral
pathogen
ideal
reduc
unwarr
antibiot
use
thu
subsequ
burden
colon
infect
multidrugresist
organ
clostridium
difficil
impact
multiplex
respiratori
panel
use
hospit
adult
mix
either
minim
improv
reduc
antibiot
use
even
among
without
infiltr
chest
radiograph
conjunct
procalcitonin
littl
publish
clinic
impact
rapid
multiplex
pcr
h
hospit
adult
patient
one
studi
adult
pediatr
patient
reduc
antibiot
prescrib
observ
howev
studi
personnel
verbal
report
test
result
question
provid
decis
withhold
prescrib
antibiot
anoth
studi
compar
rapid
averag
h
lesstim
multiplex
pcr
averag
h
adult
found
patient
treat
singl
dose
brief
cours
antibiot
adult
studi
shown
reduc
antibiot
use
small
sampl
size
uniqu
sitespecif
algorithm
turnaround
time
tat
h
analysi
influenza
compon
make
find
difficult
gener
multiplex
result
lack
improv
antibiot
util
despit
viral
confirm
inpati
set
may
part
due
prolong
tat
multiplex
pcr
panel
previous
took
hour
day
obtain
result
perform
batch
initi
influenza
test
often
provid
result
provid
antibiot
alreadi
initi
institut
previous
use
respiratori
viral
panel
xtag
rvp
rvp
result
avail
h
day
depend
collect
time
daili
batch
test
respiratori
pathogen
panel
eplex
rp
rpp
subsequ
institut
perform
specimen
receiv
shift
hypothes
switch
rvp
rpp
would
result
reduc
antibiot
initi
durat
admit
patient
particularli
patient
posit
viral
test
chest
imag
without
infiltr
retrospect
studi
conduct
two
acut
larg
tertiari
care
teach
hospit
within
academ
health
care
system
rhode
island
rhode
island
hospit
tertiari
care
center
miriam
hospit
commun
hospit
studi
protocol
approv
institut
review
board
institut
previous
institut
rvp
luminex
corpor
austin
tx
detect
influenza
viru
influenza
b
viru
respiratori
syncyti
viru
rsv
rsv
b
coronaviru
parainfluenza
viru
type
metapneumoviru
rhinoviru
enteroviru
adenoviru
sensit
specif
respect
report
tat
h
note
test
longer
commerci
avail
unit
state
replac
reduc
step
version
name
luminex
nxtag
respiratori
panel
assay
still
howev
multistep
batch
mode
assay
correspond
prolong
tat
depend
time
sampl
collect
recent
implement
rpp
genmark
diagnost
inc
san
diego
ca
includ
adenoviru
coronaviru
influenza
viru
influenza
b
viru
rsv
b
parainfluenza
viru
type
human
metapneumoviru
enterovirusrhinoviru
well
three
atyp
pathogen
bordetella
pertussi
mycoplasma
pneumonia
chlamydophila
pneumonia
rpp
concord
laboratori
develop
test
agreement
altern
multisyndrom
respiratori
panel
report
tat
h
institut
multiplex
viral
test
recommend
inpati
like
admit
wherea
rapid
influenza
ab
pcr
test
cepheid
sunnyval
ca
recommend
outpati
like
discharg
emerg
depart
ed
strict
test
algorithm
enforc
respiratori
panel
perform
institut
microbiolog
lab
result
immedi
releas
upon
assay
complet
electron
medic
record
patient
includ
analysi
year
old
assess
one
two
ed
admit
one
two
hospit
novemb
februari
rvp
group
novemb
februari
rpp
group
code
diagnos
indic
lower
respiratori
symptom
nasopharyngealswab
specimen
submit
rvp
rpp
within
h
present
two
month
consecut
influenza
season
chosen
due
high
volum
sampl
respect
patient
exclud
outpati
antibiot
prior
admiss
receiv
antibiot
indic
eg
concurr
cellul
urinari
tract
infect
bacteremia
posit
blood
cultur
ventilatorassoci
pneumonia
neutropen
fever
aspir
pneumonia
abnorm
swallow
evalu
comfortcar
primari
outcom
antibiot
initi
durat
stratifi
normal
abnorm
chest
imag
secondari
outcom
includ
inpati
admiss
length
stay
lo
death
hospit
allerg
reaction
develop
clostridium
difficil
infect
within
day
readmiss
within
day
data
extract
electron
medic
record
includ
choic
durat
administr
time
antibiot
length
therapi
lot
calcul
date
first
last
administ
dose
patient
discharg
antibiot
date
last
dose
extrapol
day
therapi
prescrib
discharg
initi
chest
imag
includ
chest
xray
chest
comput
tomographi
scan
review
categor
normal
abnorm
base
dictat
radiolog
interpret
imag
label
normal
interpret
indic
acut
pulmonari
process
eg
clear
lung
field
acut
cardiopulmonari
process
chronic
emphysemat
chang
without
superimpos
airspac
diseas
radiolog
interpret
indic
acut
pulmonari
process
consid
abnorm
verifi
laboratori
tat
time
specimen
collect
time
result
avail
electron
medic
record
emr
record
sampl
clinic
laboratori
data
patient
met
inclus
criteria
use
statist
analysi
hypothesi
test
statist
test
run
use
proc
glimmix
allow
fit
gener
gener
linear
model
well
deriv
p
valu
hypothesi
test
estim
mean
comparison
sa
sa
institut
inc
cari
nc
primari
secondari
outcom
gener
linear
model
lognorm
normal
binari
outcom
use
analyz
demograph
confound
variabl
test
differ
respiratori
test
period
rpp
versu
rvp
antibiot
use
assess
use
three
differ
metric
whether
antibiot
prescrib
whether
antibiot
given
test
result
number
day
prescrib
gener
linear
model
binari
outcom
use
analyz
estim
proport
patient
receiv
antibiot
respiratori
test
rpp
rvp
chest
imag
result
normalabnorm
interact
term
includ
model
allow
differ
level
chest
imag
result
normalabnorm
analysi
repeat
test
proport
patient
receiv
antibiot
emr
test
result
avail
neg
binomi
distribut
use
model
day
antibiot
viral
test
chest
imag
result
interact
term
also
includ
allow
differ
relationship
viral
test
use
antibiot
day
chest
imag
result
subanalysi
perform
test
whether
antibiot
subsequ
discontinu
analysi
run
subgroup
patient
receiv
antibiot
emr
test
result
avail
proport
patient
test
posit
admit
viral
test
perform
ed
underw
readmitt
experienc
inhospit
mortal
admit
intens
care
unit
icu
influenzaposit
treat
antivir
c
difficil
studi
posit
analyz
test
indirect
system
differ
studi
period
rpp
versu
rvp
also
analyz
length
stay
base
respiratori
test
use
interact
term
antibiot
administ
classic
sandwich
estim
use
adjust
model
misspecif
familywis
alpha
maintain
use
holm
adjust
multipl
comparison
adjust
p
valu
report
unless
otherwis
state
statist
model
run
use
proc
glimmix
allow
model
gener
gener
linear
model
well
deriv
p
valu
model
fix
effect
estim
mean
comparison
sa
rvp
rpp
group
antibiot
initi
estim
model
lower
patient
normal
chest
imag
compar
abnorm
chest
imag
respect
p
patient
normal
imag
antibiot
initi
significantli
lower
rppposit
group
compar
rvpposit
group
ci
ci
respect
p
fig
patient
abnorm
chest
imag
differ
antibiot
initi
posit
rvp
rpp
test
result
ci
ci
respect
p
patient
normal
imag
proport
receiv
antibiot
test
result
emr
lower
rppposit
group
rvpposit
group
ci
ci
respect
p
patient
abnorm
chest
imag
proport
receiv
antibiot
test
result
lower
rppposit
group
rvpposit
group
ci
respect
p
differ
antibiot
day
rvpposit
rppposit
patient
abnorm
chest
imag
receiv
antibiot
result
respiratori
test
avail
day
ci
day
ci
respect
p
normal
chest
imag
day
ci
day
ci
respect
p
patient
receiv
antibiot
differ
atyp
coverag
rvpposit
rppposit
group
respect
p
tabl
four
patient
posit
atyp
bacteria
three
mycoplasma
pneumonia
one
chlamydophila
pneumonia
rpp
receiv
appropri
coverag
patient
rvp
rppneg
result
differ
proport
hospit
ci
ci
respect
p
howev
posit
test
less
frequent
admit
ed
rpp
group
compar
rvp
group
ci
ci
respect
p
patient
receiv
antibiot
differ
length
stay
lo
rvpposit
rppposit
patient
day
ci
day
day
ci
day
respect
p
patient
initi
antibiot
decreas
seen
lo
rvpposit
rppposit
group
day
ci
day
day
ci
day
respect
unadjust
p
adjust
abnorm
imag
p
fig
patient
influenza
b
rvp
group
rpp
group
receiv
oseltamivir
p
allerg
reaction
antibiot
observ
either
group
signific
differ
posit
c
difficil
test
hospit
readmiss
death
hospit
tabl
implement
respiratori
pathogen
test
result
avail
h
associ
reduct
antibiot
initi
hospit
admiss
observ
chang
lot
lo
date
clinic
impact
studi
respiratori
multiplex
pcr
assay
posit
outcom
pediatr
patient
focus
influenza
test
oseltamivir
use
impact
syndrom
test
antibiot
use
adult
variabl
one
metaanalysi
overal
reduct
lo
observ
differ
hospit
admiss
signific
reduct
antibiot
initi
lot
observ
howev
four
studi
referenc
address
antibiot
use
assay
tat
h
three
found
reduct
antibiot
lot
one
show
decreas
antibiot
initi
subgroup
analysi
patient
whose
test
result
prior
antibiot
administr
thu
assay
tat
respiratori
pathogen
alon
clearli
establish
factor
reduc
antibiot
use
import
sinc
sever
multiplex
syndrom
assay
exist
abil
perform
test
random
access
fashion
specimen
come
lab
rather
daili
batch
test
reliabl
tat
well
bacteri
target
may
critic
move
needl
antibiot
use
consist
rapid
result
multiplex
assay
may
allow
coordin
decis
make
provid
avail
clinic
data
chest
radiograph
biomark
data
studi
build
previou
find
chest
imag
strong
predictor
antibiot
administr
even
though
radiographi
reliabl
distinguish
bacteri
viral
infect
demonstr
clear
reduct
antibiot
initi
patient
rapid
rpp
normal
chest
imag
may
reflect
increas
depend
confirmatori
diagnost
test
enhanc
provid
confid
withhold
antibiot
patient
abnorm
imag
antibiot
initi
similar
rvpposit
rppposit
group
rppposit
patient
abnorm
chest
imag
prescrib
antibiot
initi
test
result
patient
empir
antibiot
initi
within
minut
test
result
neither
reduct
durat
earli
discontinu
observ
physician
may
feel
comfort
stop
antibiot
initi
base
clinic
assess
present
ed
patient
viral
infect
clinic
improv
antibiot
may
reason
ed
physician
withhold
empir
antibiot
nonsept
patient
without
evid
focal
infiltr
result
multiplex
assay
becom
avail
multiplex
pcr
may
also
help
guid
choic
empir
therapi
azithromycin
commonli
prescrib
antibiot
time
period
atyp
coverag
provid
patient
rvpposit
rppposit
group
howev
fewer
patient
atyp
organ
identifi
rpp
rais
question
whether
clinician
awar
pathogen
avail
rpp
assay
physician
may
consid
withhold
atyp
antibiot
coverag
except
case
legionella
pneumophila
clinic
suspect
set
abnorm
chest
imag
use
multiplex
pcr
alon
guid
antibiot
therapi
less
immedi
clear
sinc
confirm
viral
pathogen
may
insuffici
evid
provid
withhold
stop
antibiot
given
concern
regard
potenti
bacteri
coinfect
though
current
perform
institut
implement
biomark
procalcitonin
part
clearli
defin
diagnost
algorithm
may
help
determin
whether
bacteri
coinfect
like
earlier
discontinu
possibl
though
use
controversi
decis
support
tool
within
emr
clinician
educ
diagnost
manag
team
aid
develop
test
algorithm
interpret
realtim
stewardship
may
improv
antibiot
util
diagnost
stewardship
effort
syndrom
respiratori
test
typic
reserv
inpati
like
admit
institut
may
also
help
reduc
inpati
admiss
disposit
unclear
given
faster
consist
tat
rpp
frequent
order
ed
rvp
fewer
patient
posit
rpp
admit
wherea
proport
admit
patient
neg
test
equival
rvp
rpp
group
rapid
confirm
viral
etiolog
may
increas
provid
comfort
discharg
ed
note
drop
hospit
admiss
rppposit
patient
ed
account
approxim
avoid
admiss
studi
period
time
rpp
perform
adult
patient
respiratori
viral
symptom
within
h
ed
present
cost
approxim
per
rpp
estim
nation
averag
per
inpati
admiss
stay
communityacquir
pneumonia
prevent
unnecessari
admiss
would
account
cost
perform
rpp
clinic
set
estim
account
potenti
cost
save
associ
reduc
antibiot
usag
includ
reduc
pharmaci
cost
need
laboratori
monitor
antibiot
level
indic
possibl
c
difficil
infect
rapid
molecular
detect
respiratori
pathogen
initi
critic
expens
identifi
potenti
resourc
cost
save
intervent
addit
syndrom
respiratori
test
expedit
patient
cohort
optim
isol
room
increas
abil
track
epidemiolog
trend
studi
number
limit
due
retrospect
natur
confound
may
present
lot
defin
discret
day
antibiot
receiv
thu
differ
antibiot
durat
smaller
interv
may
gone
undetect
patient
posit
test
result
admit
hospit
select
primari
analysi
allow
clinic
comparison
admit
neg
test
result
evalu
chest
imag
deem
abnorm
thu
potenti
overemphas
impact
minim
radiograph
chang
subject
abnorm
imag
howev
method
conserv
establish
normal
imag
note
increas
detect
influenza
rpp
like
fewer
initi
rapid
influenza
test
perform
popul
compar
rvp
rapid
influenza
pcr
avail
season
asthma
preval
rppposit
group
possibl
reflect
increas
use
rpp
cohort
howev
proport
patient
asthma
receiv
antibiot
significantli
differ
ed
physician
recommend
order
rvp
rpp
patient
like
admit
thu
possibl
lower
likelihood
admiss
rppposit
group
reflect
ed
physician
poorli
predict
patient
like
admit
howev
admiss
rate
similar
among
patient
neg
test
result
patient
rvp
group
admit
icu
howev
account
higher
level
care
chang
conclus
primari
outcom
final
differ
observ
readmiss
inhospit
mortal
posit
c
difficil
test
result
like
due
low
frequenc
event
conclus
implement
rpp
adult
popul
provid
result
fast
enough
clinic
action
reduc
inpati
admiss
combin
neg
chest
imag
posit
test
result
associ
reduc
initi
inappropri
antibiot
case
diagnost
uncertainti
still
challeng
distinguish
respiratori
viral
infect
bacteri
coinfect
rpp
coupl
input
diagnost
manag
team
antibiot
stewardship
program
